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Efficacy and Safety of Drug Eluting Stents in the Real World: 8 Year Follow Up
Denise Pellegrini
Hospital São Lucas PUC, Porto Alegre, Brazil
Introduction: Drug eluting stents have been used in daily practice since 2002, with clear
advantage in reducing the risk of target vessel revascularization, with the impressive
reduction of 50% to 70% in restenosis rate. However, the occurrence of late thrombosis
could compromise results in the long term, especially if the risk of this eventwere sustained
over the years. In this context, the registry of clinical practice gains special value.
Objective: Evaluation of efﬁcacy and safety of drug-eluting stents in the real world.
Methods: We report the ﬁndings of all patients that underwent percutaneous coro-
nary intervention with a drug eluting stent in the period from January 2002 to April
2007, and followed up for 8 years. Drug eluting stents were used in accordance with
the clinical and interventional cardiologist decision and availability of the stent.
Results: A total of 611 patients were included, with clinical follow-up obtained for
96.2% up to 8 years. Total mortality was 8,7%. Non-fatal infarction occurred in 4.3 %
of the cases. Target vessel revascularization was 12.4% and the target lesion revascu-
larization 8%. The rate of stent thrombosis was 2.1%. There were no new episodes of
stent thrombosis after the ﬁfth year of follow-up. Comparative subanalysis showed no
outcome differences between the stents Cypher, Taxus and Endeavor.
Conclusion: These ﬁndings indicate that drug eluting stents remain safe and effective
at very long term follow-up. Patients in the “real world” may beneﬁt from drug eluting
stenting with excellent results in the long-term.
CRT-605*
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Presenting with ST-Segment Elevation Myocardial Infarction, BVS STEMI FIRST Study
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Netherlands
Aims: We evaluated the, feasibility and the acute performance of the bioresorbable
vascular scaffolds (BVS) for treatment of patients presenting with ST-segment
elevation myocardial infarction (STEMI).
Methods and Results: The present investigation is a prospective, single-arm, single-
centre study, reporting data after BVS implantation in STEMI patients. Quantitative
coronary angiography and optical coherence tomography (OCT) data were evaluated.
Clinical outcomes are reported at 6 months follow-up. The intent-to-treat population
comprises a total of 49 patients. The procedural success was 97.9%. Pre-procedure
TIMI-ﬂow was 0 in 50.0% of the patients; after BVS implantation a TIMI-ﬂow III
was achieved in 91.7% of patients and the post-procedure percentage diameter stenosis
was 14.7  8.2%. No patients had angiographically visible residual thrombus at the
end of the procedure. OCT analysis performed in 31 patients, showing that the mean
lumen area was 8.021.92 mm2, minimum lumen area 5.951.61 mm2, mean
incomplete scaffold apposition area 0.1180.162 mm2, mean intraluminal defect area
0.0130.017 mm2, mean percentage malapposed struts per patient 2.803.90%.
Scaffolds with >5% malapposed struts were 7. Six months follow-up will be available
in Feb 2014.
Conclusion: a. : In the present series the BVS implantation in patients presenting
with acute myocardial infarction appeared feasible, with high rate of ﬁnal TIMI-ﬂowIII and good acute scaffold apposition on OCT. Medium term follow-up data will be
presented at CRT.Renal Denervation
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Arterial Stiffness as an Early Marker of Renal Sympathetic Denervation Effectiveness
Andrius Berukstis,1 Nerijus Misonis,1 Ligita Ryliskyte,1 Rokas Navickas,1
Kamile Cerlinskaite,2 Aleksandras Laucevicius1
1Vilnius University, Clinic of Cardiovascular Medicine, Vilnius, Lithuania; 2Vilnius
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Background: Renal sympathetic denervation (RSD) has been reported to reduce
blood pressure in patients with resistant arterial hypertension, although it takes time
before noticeable changes after the procedure occur. There are several reports on late
changes in arterial stiffness after RSD. We have investigated early and late changes in
arterial stiffness after denervation searching for the markers of RSD effectiveness.
Methods: We have evaluated 20 patients with resistant arterial hypertension (age
56.27.4 years, 11 male, 9 female, mean 24-hour ambulatory blood pressure (BP) -
160/9619/16 mm Hg, using 6.11.1 antihypertensive drugs), who underwent
bilateral RSD. Arterial stiffness parameters were measured before the procedure,
during the ﬁrst 48 hours after RSD and, subsequently, after 1, 3 and 6 months.
Results: During the ﬁrst 48 hours after RSD, a signiﬁcant reduction in peripheral BP
from 182/10728/19 to 163/9517/11 mmHg (p¼0.003), and mean arterial pressure
(MAP) from 13523 to 11613 mmHg (p¼0.0003) was observed. RSD signiﬁcantly
reduced carotid-femoral pulse wave velocity (PWV) during the ﬁrst 48 hours from
11.22.9 to 9.72.1 m/s (p¼0.0004) and carotid-radial PWV from 10.32.4 to
8.81.4 (p¼0.008). Analysis of variance revealed the MAP independent improvement
of PWV during 48 hours after RSD (r¼-0.07, p¼0.8). Furthermore, a substantial
decrease in carotid-femoral PWV has been recorded at 1, 3 and 6 months, 9.52.3
(p<0.001), 9.412.78 (p¼0.006) and 8.942.03 (p<0.001), respectively. In addition,
reduction in carotid-radial PWV sustained at 1, 3 and 6 months, 9.241.33
(p¼0.051), 8.991.65 (p¼0.063) and 8.671.20 (p¼0.007), respectively.
Conclusion: Changes in arterial stiffness occur early after RSD. During the ﬁrst 48
hours after the procedure, a signiﬁcant reduction of arterial stiffness parameters, which
remained at 1, 3 and 6 months have been noted. RSD effects on PWV were inde-
pendent from blood pressure changes.
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Renal Denervation with a Percutaneous Bipolar Radiofrequency Balloon Catheter in
Patients with Resistant Hypertension: Efficacy and Safety Results From the
REDUCE-HTN Trial
Horst Sievert,1 John Ormiston,2 Ian Meredith,3 Meital Mazor4
1CardioVascular Center Frankfurt, Frankfurt, Germany; 2Mercy Angiography, Auckland,
New Zealand; 3MonashHEART, Monash Health, Melbourne, Australia; 4Vessix Vascular
and Boston Scientiﬁc, Laguna Hills, CA
Background: The Vessix Renal Denervation System (Boston Scientiﬁc, Natick, MA)
consists of a radiofrequency generator and a balloon catheter mounted with a bipolar
radiofrequency electrode array. The objective of the REDUCE-HTN Clinical Study is
to evaluate the performance of the Vessix System in treating medication-resistant
hypertension.










YMethods: The REDUCE-HTN trial is a prospective, multicenter, single-arm study.
Patients were required to have ofﬁce-based systolic blood pressure (BP) 160 mmHg
despite compliance with 3 antihypertensive medications at maximally tolerated
doses. The primary efﬁcacy endpoints were the 6-month reductions in ofﬁce-based
systolic and diastolic BPs, and reductions in systolic and diastolic BP as measured by
24-hour ambulatory monitoring. Acute safety (ie, freedom from renal artery dissection
or perforation requiring stenting or surgery, renal artery infarction or embolus, cere-
brovascular accident, myocardial infarction, or sudden cardiac death at the time of the
procedure) and long-term safety, including renal artery patency and renal function,
were assessed.
Results: Mean baseline ofﬁce BP was 182.418.4/100.114.0 mmHg among
enrolled patients (N¼146; age 58.510.5 years, 61% men, 27.4% with type 2 dia-
betes). No patients experienced any of the prespeciﬁed acute safety events. Among 139
patients with 6 month data, mean ofﬁce BP was reduced to 157.723.8/
89.415.7 mmHg; a reduction of 24.622.3/10.312.9 mmHg (p<0.0001). Mean
baseline ambulatory BP was 153.015.1/87.513.2 mmHg (n¼103); at 6 months it
was reduced by 8.514.6/5.99.2 mmHg (n¼67; p<0.0001). Renal artery patency by
duplex ultrasound at 6 months was 99.1%. Mean estimated glomerular ﬁltration rate
(eGFR) changed -0.916.5 at 6 months, and 11% of patients (15/136) had a
reduction in eGFR >25%. Six-month results for the full cohort of enrolled patients are
expected to be available at the time of presentation.
Conclusions: Primary endpoint results from the REDUCE-HTN trial demonstrate
that the Vessix System is an efﬁcacious method for treating resistant hypertension. No
acute safety endpoint events were observed and 6-month patency and renal function
results are favorable.
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Pooled 3-Year Symplicity Htn-1 and Symplicity Htn-2 Results and Diabetes Subgroup
Analysis
Richard Katholi,1 Murray Esler,2 Henry Krum,3 Krishna Rocha-Singh,1
Markus Schlaich,2 Michael Böhm,4 Felix Mahfoud4
1Prairie Education and Research Cooperative, Springﬁeld, IL; 2Baker IDI Heart and
Diabetes Institute, Melbourne, Australia; 3Monash University, Melbourne, Australia;
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Background: Treatment resistant hypertension (rHTN) is deﬁned as uncontrolled
blood pressure despite use of 3 antihypertensive drugs including a diuretic. The
sympathetic nervous system plays an important role in the pathogenesis of hyper-
tension. The Symplicity renal denervation system uses a percutaneous approach to
deliver low-power radiofrequency energy to interrupt the efferent sympathetic and
afferent renal nerves. Up to 3 year follow-up of pooled patient level data are available to
evaluate renal denervation (RDN) efﬁcacy and safety, including patients with type II
diabetes mellitus (DM).
Methods: The Symplicity HTN-1 and Symplicity HTN-2 prospective, multicenter
trials enrolled rHTN subjects with a systolic BP (SBP) 160 mm Hg; (150 mm
Hg for DM subjects). Subjects remained on their antihypertensive drugs for 6
months after which changes were allowed as clinically indicated. A subset of subjects
in Symplicity HTN-1were consented to 3 years; all subjects randomized to im-
mediate RDN on Symplicity HTN-2 were followed to 3 years post-RDN. Change
from baseline BP was measured at each follow-up and all safety events were
evaluated.
Results: Baseline characteristics of 128 subjects followed through 3 years include
mean age, 58 years; 34% DM, 38% female, and body mass index of 32 kg/m2. Mean
baseline SBP was 175.7  14.1 mm Hg and was reduced by 24.6  22.7 mm Hg at 6
months (p<0.01). This BP reduction was sustained at 3 years with a mean drop of
32.2  19.7 mm Hg (p<0.01). DM and non-DM subjects had similar baseline SBP
and experienced a similar and signiﬁcant reduction in SBP at 3 years (-30.0 mm Hg vs
-33.3 mm Hg, respectively, p<0.001 compared with baseline, p¼0.37 between DM
and non-DM subjects). Procedure-related adverse events included 2 dissections (1
before radiofrequency energy was delivered), and 1 access site hematoma. Serious
adverse events included 6 deaths, 4 renal failure cases (all resolved), and 1 stenosis
requiring stenting.
Conclusions: The data indicates that treatment of rHTN with the Symplicity catheter
provides safe and sustained reductions in SBP through 3 years. The reduction in SBP
was similar in both DM and non DM subjects.*Indicates iMPACT Trial Accepted for Oral PresentationCRT-610
Bipolar Multi-Electrode Balloon Catheter Radiofrequency Renal Denervation with the
Vessix System: Preclinical Safety Evaluation
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Background: A bipolar multi-electrode balloon catheter radiofrequency (RF) renal
denervation system offers advantages of short procedure time and low power to
minimize risk of non-target tissue thermal injury. We report a preclinical safety study
of a 7 French (F) system in a domestic swine model.
Methods: The 7F device was used to treat the renal arteries of 20 pigs, with over-
lapping treatments in the proximal 12 mm to mimic clinical balloon overlap. Each
histopathology cohort (30 & 90 day follow-up) had 4 RF-treated and 3 sham-treated
(no RF energy delivered) pigs and response of artery and surrounding nerves to
bilateral treatment was examined (28 arteries). Scanning electron microscopy was used
to examine the renal artery ﬂow surface for endothelialization, with unilateral whole
artery treatment with proximal overlap: RF on one side and sham on the other (3 pigs/
cohort; 12 arteries). Treatment duration was 30 seconds. Animals received 2 to 3
treatments per artery depending on artery length. Histology on all 40 kidneys and
assessment for non-target injury was undertaken in all 20 pigs.
Results: Renal artery injury was transmural and segmental, with variable percentages
of the circumference (<10% to >90%, typically 30-50%) demonstrating overlying
nerve injury and associated segmental neointimal hyperplasia. No increase in thermal
injury was observed in overlapped vs single-treatment segments. At 30 days, “islands”
of necrotic media remained, but at 90 days healing was essentially complete with
mature replacement ﬁbrosis. Inﬂammatory activity was mild at 30 days and minimal by
90 days. Maximum lumen stenosis (all sections, both time points) was 17.7%, he-
modynamically trivial, and typically <10%. Endothelialization was focally incomplete
at 30 days, but completely conﬂuent at 90 days. Sham-treated arteries showed only
mild focal mechanical injury, which was also seen with thermal treatment. Kidney
histology demonstrated no injury, and there was no injury to renal veins, ureters,
adrenal glands, psoas muscles, peritoneum or intestines.
Conclusion: Safety of the Boston Scientiﬁc Vessix renal denervation system in 7F
conﬁguration was demonstrated for both single and overlap treatment.
Technology
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Poor Outcome in Patients Requiring Intra-Aortic Balloon Pump Reinsertion in
Cardiogenic Shock
Edward Howard, Jill Steiner, Rebecca Torguson, Julio Panza, Howard Cooper
MedStar Washington Hospital Center, Washington, DC
Background: Intra-aortic balloon pumping (IABP) is the most frequently utilized
form of temporary mechanical support in cardiogenic shock. Withdrawal of IABP
support occasionally precipitates hemodynamic compromise or collapse such that
IABP reinsertion is considered or performed. The outcome of patients undergoing
IABP reinsertion has not been formally studied.
Methods: Using the MedStar Washington Hospital Center Cardiac Care Unit
(CCU) database, we identiﬁed a population of patients presenting with cardiogenic
shock who required IABP reinsertion after failed wean. As a control we identiﬁed a
matched population of patients who had received only a single IABP for cardiogenic
shock. The primary outcome investigated was in-hospital mortality. Secondary out-
comes included the utilization of other temporary or permanent methods of cardiac
support, transplant, and discharge to hospice and a composite thereof.
